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Cyclooxygenase 2 (COX)-2 is induced by bacterial and viral infections and has complex, poorly under-
stood roles in anti-pathogen immunity. Here, we use a knock-in luciferase reporter model to image
Cox2 expression across a range of tissues in mice following treatment with the either the prototypical
bacterial pathogen-associated molecular pattern (PAMP), LPS, which activates Toll-like receptor (TLR)4,
or with poly(I:C), a viral PAMP, which activates TLR3. LPS induced Cox2 expression in all tissues exam-
ined. In contrast, poly(I:C) elicited a milder response, limited to a subset of tissues. A panel of cytokines
and interferons was measured in plasma of wild-type, Cox1/ and Cox2/ mice treated with LPS,
poly(I:C), MALP2 (TLR2/6), Pam3CSK4 (TLR2/1), R-848 (TLR7/8) or CpG ODN (TLR9), to establish
whether/how each COX isoform modulates speciﬁc PAMP/TLR responses. Only LPS induced notable loss
of condition in mice (inactivity, hunching, piloerection). However, all TLR agonists produced cytokine
responses, many of which were modulated in speciﬁc fashions by Cox1 or Cox2 gene deletion. Notably
we observed opposing effects of Cox2 gene deletion on the responses to the bacterial PAMP, LPS, and
the viral PAMP, poly(I:C), consistent with the differing abilities of the PAMPs to induce Cox2 expression.
Cox2 gene deletion limited the plasma IL-1b and interferon-c responses and hypothermia produced by
LPS. In contrast, in response to poly(I:C), Cox2/ mice exhibited enhanced plasma interferon (IFNa,b,c,k)
and related cytokine responses (IP-10, IL-12). These observations suggest that a COX-2 selective inhibitor,
given early in infection, may enhance and/or prolong endogenous interferon responses, and thereby
increase anti-viral immunity.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license. 1. Introduction
Cyclooxygenase (COX) enzymes catalyze the two-step conver-
sion of arachidonic acid to the unstable prostaglandin (PG) inter-
mediate PGH2, which is then further converted to a range of
prostanoid mediators that include PGE2, prostacyclin (PGI2) and
thromboxane (TXA2). Two COX isoforms, which catalyze identical
reactions, exist. COX-1 is constitutively expressed in many tissues,
and generally plays a role in homeostatic function [1,2]. In contrast,COX-2 is generally not expressed in most healthy tissues but is rap-
idly induced in response to mitogens [3] and cytokines [4] and is
often present in elevated levels at sites of inﬂammation. COX-2
produces prostanoids that contribute to vasodilation, increased
vascular permeability, leukocyte chemotaxis, fever and that poten-
tiate nociception. Indeed, COX-2 is the target of both traditional
non-steroidal anti-inﬂammatory drugs (NSAIDs) such as aspirin
and ibuprofen, which inhibit both COX-1 and COX-2, and of newer
COX-2 selective inhibitors such as celecoxib. These agents are
widely used for the symptomatic control of pain and inﬂammation,
particularly in patients with arthritis, reﬂecting COX-2 induction in
the inﬂamed arthritic joint.
In addition to its expression in sterile inﬂammation, it is clear
that COX-2 is induced by pathogens. For example, gram-negative
bacteria, or lipopolysaccharide (LPS), which activates the prototyp-
ical bacterial pattern recognition receptor Toll-like receptor (TLR)4,
can induce COX-2 expression both in isolated cells [5,6] and in vivo
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COX-2 in cultured cells [8–10]. However, no systematic compari-
son of the ability of bacterial and viral pathogen-associated molec-
ular patterns (PAMPs) to induce COX-2 in different tissues has been
described. Moreover, whilst prostaglandins are recognized as
important modulators of the immune system [11], there is no
study that compares the roles of COX-1 versus COX-2 in inﬂamma-
tory responses induced by viral and bacterial PAMPs. Here, we use
a ‘‘knock-in’’ Cox2 luciferase reporter mouse[7], in which luciferase
activity expressed from the endogenous Cox2 promoter reﬂects
Cox2 expression, to both visualize and quantify the tissue distribu-
tion of LPS- and poly(I:C)-induced Cox2 gene expression. We then
explore the role of COX-1- and COX-2-derived prostanoids in mod-
ulating the inﬂammatory response to speciﬁc PAMPs, using mice
deﬁcient in either COX isoform.2. Methods
2.1. Animals
Cox1/ [1], Cox2/ [12] and Cox2fLuc/+ mice [7] were back-
crossed onto a C57Bl/6J background and identiﬁed by genomic
PCR. Experiments were performed on 10–12 week old male and fe-
male mice. Animal procedures were conducted in accordance with
Animals (Scientiﬁc Procedures) Act 1986 and after local ethical re-
view by the Imperial College Ethical Review Panel or the UCLA Ani-
mal Research Committee, as appropriate for individual
experiments.
2.2. Bioluminescent imaging
Cox2fLuc/+ mice were injected with poly(I:C) (8 mg/kg; i.p.; Sig-
ma, UK), LPS (from Escherichia coli serotype 055:B5; 0.1 or
10 mg/kg; i.p.; Sigma, UK) or vehicle (saline) under brief isoﬂurane
anesthesia. 4 h later, D-luciferin (125 mg/kg; i.p.; Xenogen, USA)
was administered. After a further 15 min, the dorsal skin was
shaved and bioluminescent emission from this area was recorded
over 3 min, using an IVIS imaging system (Xenogen, USA). Animals
were then euthanized by isoﬂurane overdose and tissues were rap-
idly dissected and arranged on cell culture dishes, following which
luciferase activity was imaged ex vivo. In both cases, collected pho-
ton number and images were analyzed using Living Image soft-
ware (Perkin Elmer, USA) and quantiﬁed as the peak photon
release/pixel detected from each tissue.
2.3. Luciferase activity assays
After bioluminescent imaging, tissues were snap frozen for bio-
chemical measurement of luciferase activity. Tissues were dissoci-
ated using a Precellys24 bead homogenizer and the supernatants
loaded into white 96 well microtitre plates. The luminescence
was then read after injection of Luciferase Assay Reagent (Promega,
UK). Protein concentration of homogenates was determined using
the bicinchoninic acid method (Perbio, UK) and luciferase activity
was normalized for protein concentration.
2.4. Animal condition, body temperature and blood counts
Ligands to TLR2/1 (Pam3CSK4; 2 mg/kg; Invivogen, UK), TLR2/6
(MALP2; 60 lg/kg; Enzo Lifesciences, UK), TLR3 (poly(I:C); 8 mg/
kg), TLR4 (LPS; 0.1 or 10 mg/kg), TLR7 (R848; 2 mg/kg; Enzo Life-
sciences, UK), TLR9 (CpG ODN 1826; 2 mg/kg; Invivogen, UK) or
vehicle (saline) were administered to wild-type, Cox1/ and
Cox2/ mice by intraperitoneal injection, under brief isoﬂurane
anesthesia. Immediately prior to injection, core body temperaturewas measured using a rectal thermometer. After 4 h, the gross
physical condition of mice was scored (0–5) by two independent
observers based on coat condition (e.g. piloerection), behavior
(e.g. activity, response to investigator) and posture (e.g. hunching).
Mice were then euthanized by CO2 narcosis, and body temperature
immediately measured. Blood was collected, from the vena cava,
into heparin (10 U/ml ﬁnal; Leo Laboratories, UK). Whole blood
cells counts were obtained using a commercial veterinary bio-
chemistry service (IDEXX Laboratories, UK) and plasma separated
from the remainder by centrifugation for cytokine analysis.
2.5. Plasma cytokine levels
Plasma levels of IL-1b, IL-4, IL-5, IL-10, IL-12, IFNc, TNFa and KC
were determined using a multiplex immunoassay system (Meso
Scale Diagnostics, USA). Plasma levels of IP-10 and IFNk (R&D Sys-
tems, USA) and IFNa and IFNb (PBL InterferonSource, USA) were
determined by individual ELISAs.
2.6. Isolated blood assays
Untreated wild-type, Cox1/ and Cox2/ mice were eutha-
nized by CO2 narcosis and whole blood collected as above then
treated with ligands to TLR2/1 (Pam3CSK4; 1 lg/ml), TLR2/6
(FSL-1; 1 lg/ml; Invivogen, UK). TLR3 (poly(I:C); 10 lg/ml), TLR4
(LPS; 1 lg/ml) or TLR7 (imiquimod; 10 lg/ml; Invivogen, UK), the
NOD1 ligand C12-iE-DAP (1 lg/ml), mouse IL-1b (10 ng/ml) or sal-
ine. Treated blood was incubated for 24 h at 37 C, after which the
plasma fraction was separated by centrifugation and IP-10 and KC
levels determined.
2.7. Statistics and data analysis
Data were analyzed using Prism 5.01 (GraphPad software, USA).
Statistical signiﬁcance was determined by two-way ANOVA with
Dunnett’s post-hoc test unless otherwise stated, and data sets con-
sidered different if p < 0.05. Each n value represents a data point
from a separate animal.3. Results
3.1. Cox2 gene induction by prototypical viral and bacterial PAMPs
Cox2 gene expression is increased globally in Cox2fLuc/+ animals
treatedwith LPS, a TLR4 ligand [7]. In the current study, we extended
our earlier observations and used two doses of LPS to observe a
graded, dose-dependent increase in gene expression (Fig. 1A). When
surface luminescence values for intact tissues were measured, the
following tissues displayed a robust response (P2-fold increase ver-
sus vehicle-treated mice) to LPS (0.1 mg/kg): aorta, heart, liver, lung
and spleen (Fig. 1A). When a larger LPS dose (10 mg/kg) was
administered, all studied tissues measured displayed P2-fold in-
crease in Cox2 gene expression (versus vehicle) with the following
rank order spleen heartP liver > lungP aorta > skin kid-
ney stomach thymus  gut brain. In contrast to results
obtained with LPS, the viral PAMP/TLR3 ligand, poly(I:C), at a dose
(8 mg/kg), close to the maximum tolerated dose [13], produced only
a modest induction of Cox2 gene expression; signiﬁcant induction
was only apparent in the spleen (Fig. 1B).
Surface luminescence valuesdonot always reﬂect the tissue activ-
ity in thismodel, since tissue absorbance of emitted bioluminescence
and penetration of substrate in vivo inﬂuence measured lumines-
cence. For this reason, we also measured luciferase activity, driven
from the Cox2 promoter, in tissue homogenates. These data (Supple-
mentary Fig. 1) conﬁrm those obtained by surface luminescence
Aorta Blood Brain Gut Heart Kidney Liver Lung Skin Spleen Stomach Thymus
0
2
4
6
8
10
150
300
Vehicle
Poly(I:C) 8mg/kg
LPS 0.1mg/kg
LPS 10mg/kg
C
O
X-
2 
in
du
ct
io
n
(fo
ld
 c
ha
ng
e)
0.80.60.40.2
x106
(tissues)
Luminescence
(photons/sec/cm2/spr)
Vehicle Poly(I:C) 8mg/kg LPS 0.1mg/kg
Ex
 v
iv
o
is
ol
at
ed
 ti
ss
ue
s
In
 v
iv
o
do
rs
al
 s
ki
n
LPS 10mg/kg
x107
(whole mice)
(A)
(B)
aorta
blood
thymus
lung
skin
stomach
intestines
heart
spleen
kidney
liver
brain
aorta blood
thymus
lung
skin
stomach
intestines
heart
spleen
kidney
liver
brain
aorta
blood
thymus
lung
skin
stomach
intestines
heart
spleen
kidney
liver
brain
aorta blood
thymus
lung
skin
stomach
intestines
heart
spleen
kidney
liver
brain
*
*
* *
*
**
*
** *
* *
*
*
*
* *
Fig. 1. Expression from the Cox2 gene induced in mice by prototypical bacterial and viral PAMPs. Cox2 promoter-driven gene expression was measured, by bioluminescent
imaging of skin in vivo and isolated tissues ex vivo, in Cox2fLuc/+ luciferase reporter mice (A) and quantiﬁed as the fold-change in luminescence (B). The bacterial PAMP, LPS,
produced a dose-dependent induction of Cox2 gene expression across a broad range of tissues. The viral PAMP, poly(I:C), in contrast, had little effect on Cox2-driven gene
expression in most tissues, but produced a selective Cox2 induction in the spleen. Data are expressed as means ± s.e.m. from n = 4 to 5 individual animals per treatment.
⁄p < 0.05 vs. vehicle.
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poly(I:C)-induced Cox2 induction.3.2. Modulatory role of COX-2 on physical features of sepsis induced by
LPS in vivo
Wild-type mice treated with LPS displayed observable ‘physical
condition’ responses, including hunching, inactivity and piloerec-
tion (Fig. 2A). The physical condition response to LPS was accom-
panied by a decrease in body core temperature, reﬂecting loss of
thermoregulation (Fig. 2B), and reduced circulating lymphocyte
and platelet counts (versus vehicle treatment), suggesting tissue
lymphocyte sequestration and intravascular coagulopathy, respec-
tively (Supplementary Fig. 2). These LPS-induced behavioral and
body temperature changes were COX-2-dependent, but not COX-
1 dependent, since they were strongly suppressed in Cox2/, but
not Cox1/ mice (Fig. 2A and B).
In contrast to the results for LPS, other PAMPs tested did not af-
fect the gross physical condition or body core temperature of themice (Fig. 2A and B). Nonetheless, like LPS, Pam3CSK4, poly(I:C)
and R-848 produced lymphocytopenia (Supplementary Fig. 2),
whilst MALP-2, poly(I:C), R-848 and CpG ODN produced an in-
crease in circulating neutrophils, probably reﬂecting mobilization
from the bone marrow (Supplementary Fig. 2). Cox1 or Cox2 dele-
tion did not affect any of these features.3.3. PAMPs produce speciﬁc patterns of cytokine and interferon
response in vivo
Each tested PAMP produced a speciﬁc pattern of plasma
cytokine response, in agreement with reports from previous
in vivo studies [14] and reﬂecting the distinct tissue distribution
and signaling pathways of each TLR [15]. The pro-inﬂammatory
cytokines IL-1b (Fig. 2C), TNFa and KC and the anti-inﬂamma-
tory cytokine IL-10 (Supplementary Fig. 3) were increased in
plasma of mice treated with LPS, but not in mice treated with
the other PAMPs. IL-5 was also increased by LPS, as well as
Pam3CSK4, whilst plasma IL-4 was elevated in mice treatedwith
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Fig. 2. Effect of Cox1 and Cox2 gene deletions on the physiology of mice treated with bacterial and viral PAMPs. Wild-type, Cox1/ and Cox2/ mice were treated with a
range of bacterial and viral PAMPs. After 4 h ‘‘animal condition’’ was scored (A), and core body temperature change (B) and plasma IL-1b levels measured (C). Only LPS
produced an apparent of loss of condition in mice; this phenotype was accompanied by a hypothermic response and increased plasma IL-1b levels. Cox2 gene deletion
protected mice against each of these responses. Data are expressed as means ± s.e.m. from n = 6 to 12 individual animals per treatment. ⁄p < 0.05 vs. wild-type; #p < 0.05 vs.
vehicle-treated wild-type.
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IFNs are intrinsically associated with viral infection [15]. There-
fore, as expected, plasma IFNa levels were increased in mice
treated with the viral PAMPs poly(I:C) and R-848. IFNa levels
also tended to be increased in mice treated with the bacterial
PAMPs LPS and CpG ODN (Fig. 3A). In wild-type mice, LPS and
R-848 produced a signiﬁcant increase in plasma IFNc levels
(Fig. 3B), but only MALP-2 produced a strong increase in the
type III interferon, IFNk (Fig. 3C).3.4. Complex role of COX-2 in cytokine and interferon responses to
viral and bacterial PAMPs
To understand how prostanoids produced by COX-1 and COX-2
modify the cytokine responses to speciﬁc viral and bacterial
PAMPs, we performed studies using mice deﬁcient in either iso-
form. In line with what was seen with physical condition and body
temperature, in mice-treated with LPS, the IL-1b (Fig. 2C) IL-5
(Supplementary Fig. 3) and IFNc responses were markedly
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Fig. 3. Effect of Cox1 and Cox2 gene deletions on circulating interferon levels in mice treated with bacterial and viral PAMPs. Wild-type, Cox1/ and Cox2/ mice were
treated with a range of bacterial and viral PAMPs. After 4 h, the levels of IFNa (A), IFNc (B) and IFNk (C) were measured in plasma. In general, the viral PAMPs, poly(I:C), R-848
and CpG ODN, were better able to stimulate interferon production than their bacterial counterparts. In wild-type mice, poly(I:C) increased IFNa levels and tended to increase
IFNc levels, however, in each case the response was markedly increased in Cox2/mice. A similar pattern was true for poly(I:C)-induced IFNk. In contrast, the IFNc response
to LPS was suppressed by Cox2 deletion, whilst Cox1 gene deletion limited the IFNa response to R-848 and CpG ODN. Data are expressed as means ± s.e.m. from n = 6 to 12
individual animals per treatment. ⁄p < 0.05 vs. wild-type; #p < 0.05 vs. vehicle-treated wild-type.
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296 ± 43 pg/ml; Cox2/ + LPS: 109 ± 13 pg/ml). By contrast, dele-
tion of Cox1 did not alter the cytokine response to LPS, perhaps
reﬂecting an overwhelming Cox2 induction by this stimulus
(Fig. 1). More modest and variable roles for COX enzymes were
noted in cytokine responses to other bacterial PAMPs, with effects
of Cox1 and Cox2 deletion noted on speciﬁc IL-5 (Supplementary
Fig. 3), IFNk (Fig. 3) and IFNb responses (Supplementary Fig. 4).Cytokine responses to viral PAMPs exhibited a distinctly differ-
ent pattern of response to Cox1 and Cox2 deletion. The most pro-
nounced interactions was an increase of upto 6-fold in the IFNa,
IFNc and IFNk (Fig. 4) and IFNb (Supplementary Fig. 4) responses
to poly(I:C) in Cox2/ mice. This suggests that COX-2-derived
prostanoids act to limit TLR3-mediated IFN release, and contrasts
sharply with the pro-inﬂammatory role of COX-2 in LPS cytokine
responses. In agreement, levels of the IFN-associated cytokine
254 N.S. Kirkby et al. / Biochemical and Biophysical Research Communications 438 (2013) 249–256IL-12, and the IFN response cytokine IP-10 were also increased by
Cox2 deletion in poly(I:C)-treated mice, as were basal levels of IL-
12 in vehicle-treated animals (Supplementary Fig. 4). Whilst there
was a tendency for IFNa to be increased in poly(I:C) treated Cox1/
 mice, this effect was less robust than that seen in Cox2/ mice
and was in opposition to reduced R-848 and CpG ODN IFNa re-
sponses in Cox1/ mice (Fig. 3). This further illustrates the speci-
ﬁcity of the interactions between COX-1/2 activity and PAMP/TLR
pathways. These effects of Cox1/2 gene deletion on IFNs and related
cytokines were associated with a systemic effect, since no change
in IP-10 was noted in whole blood stimulated with PAMPs in cul-
ture. This contrasts to the clear increase in KC seen in whole blood
stimulated with LPS (Supplementary Fig. 5).
4. Discussion
COX-2 is an inducible enzyme that regulates the production of
prostaglandins in inﬂammation and infection. It is increasingly rec-
ognized that COX-2 has a complex role in immune responses, the
extent of which we do not yet fully understand. In the current
study we used a mouse model in which expression from the
Cox2 gene can be imaged directly, using a luciferase reporterFig. 4. Heatmap summarizing the effect of Cox1 and Cox2 gene deletions on the physiolo
Cox1/ and Cox2/ mice were treated with a range of bacterial and viral PAMPs. Aft
measured. Data are presented as mean (n = 6–12) fold-changes from wild-type vehicle.
vehicle. Because ranges of change differ greatly for different ligands and/or responses, s‘‘knocked in’’ to the coding region of the endogenous Cox2 gene,
to compare expression after treatment with bacterial and viral
PAMPs. We present data showing that bacterial LPS caused a
pan-COX-2 induction across all studied tissues. In contrast, the vir-
al PAMP, poly(I:C), induced a much more tissue-speciﬁc and lim-
ited induction from the Cox2 gene, with increases seen only in
the spleen and stomach. These results likely reﬂect the limited dis-
tribution of TLR3 to speciﬁc immune cells, compared to broadly ex-
pressed TLR4.
In the current study, we show, for the ﬁrst time, how deletion of
Cox1 or Cox2 affects responses to a broad range of PAMPs. These
data, summarized qualitatively in Fig. 4, clearly highlight distinct
roles of COX-1 and COX-2-derived prostanoids in the modulation
of speciﬁc PAMP/cytokine responses and suggest a potentially
important role for COX-2 in anti-viral interferon responses.
In mouse models, the TLR4 ligand, LPS, induces a systemic
inﬂammatory response that includes pronounced changes in the
physical condition of the animal. Typical responses include piloe-
rection, inactivity and loss of thermoregulation. In our study these
effects were prevented by Cox2 gene deletion, consistent with pre-
vious reports [16], but not by Cox1 deletion. Importantly, these
observations reﬂect what we know about the consequences ofgy and cytokine response of mice treated with bacterial and viral PAMPs. Wild-type,
er 4 h animal condition, circulating blood cell counts and plasma cytokine levels
For clarity, color change is only shown for parameters differing signiﬁcantly from
cale bars are not shown and individual columns/rows are normalized internally.
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itors, are effective anti-pyretic drugs [17].
Whilst the other tested PAMPs did not induce notable changes
in physical condition or thermal deregulation, they did produce
cytokine changes. These effects were not ubiquitous and each
PAMP elicited a relatively speciﬁc cytokine response proﬁle
(Fig. 4). Cox1 and Cox2 gene deletion studies suggested distinct
interactions between COX-1, COX-2 and speciﬁc TLR responses.
These differences likely reﬂect both the targeting of unique cell
populations by each PAMP and the speciﬁc prostanoid pathways
associated with these targets. Consistent with the anti-inﬂamma-
tory effects of COX-2 inhibitors in man and in previous animal
studies [16] we noted that Cox2 gene deletion attenuated IL-1b,
IL-5 and IFNc responses to LPS. In contrast, the response to other
tested bacterial PAMPs were, for the most part, not consistently al-
tered by deletion of either the Cox1 or Cox2 gene.
TLR3, the receptor for poly(I:C) is highly expressed on dendritic
cells, which secrete IFNa and IL-12. These ligands, in turn, stimu-
late IFNc production in natural killer cells [14]. Interestingly,
Cox2 gene deletion enhanced poly(I:C)-induced release of type I
(IFNa, IFNb), type II (IFNc) interferons and IL-12, consistent with
an augmented dendritic cell response, as well as release of type
III interferon (IFNk) and the IFN response protein, IP-10. Indeed,
elevated basal IL-12 levels in Cox2/ mice suggest dendritic cells
may be primed for activation in these animals, consistent with pre-
vious reports that prostanoids can limit dendritic cell function and
survival [18]. TLR7 and TLR9, the receptors for the viral PAMPs R-
848 and CpG ODN, respectively, have a broader expression in the
immune system than TLR3 and couple to the MyD88 rather than
TRIF adapter protein. Unlike TLR3-mediated IFNa responses,
TLR7/TLR9 stimulated-release of IFNa was not enhanced by Cox2
gene deletion and was suppressed by Cox1 gene deletion, illustrat-
ing a complex interaction between viral PAMPs and the two COX
enzymes.
In addition to the predicted anti-inﬂammatory role of COX-2
deletion, our observations showing enhanced anti-viral interferon
responses in Cox2/ mice to poly(I:C), suggesting that COX-2
inhibitors could have disease-modifying activity in viral infections.
Interactions between COX-2 and viral infection has been suggested
in a limited number of studies; COX-2 can be induced by whole
virus in isolated cells [8–10] and COX-2 protein is increased in
biopsy specimens of viral target tissues from patients with active
viral infection [19,20]. Moreover, data from isolated cells [8,10]
and animal models suggest that COX-derived products may play
an important role in the host response. Cox2 deletion reduces mor-
tality in mice infected with inﬂuenza A [21]. Moreover, in the same
model, Cox1 deletion is associated with worsening of infection,
consistent with our data demonstrating that COX-1 can limit
TLR7/9 interferon responses. Protective effects of COX-2 inhibition
have also been described in rodent models of respiratory syncytial
virus [22] and vesicular stomatosis virus (VSV) [23]. Whilst there is
little consensus as to the mechanism(s) responsible for this effect,
limited previous data point to a role for IFN. For example, COX-2
inhibition in VSV-infected mice increases plasma IFNc and IL-12
levels [23], and treatment of hepatitis B or C patients with the
COX-1/COX-2 inhibitor indomethacin increases serum levels of
the IFN response product 2050-oligoadenylate synthetase-1 [24].
Our data may, therefore, provide a mechanistic link by which
COX-2 regulates viral infection as a result of modulation of innate
immune recognition and subsequent interferon response.
Taken together, this study is the ﬁrst to provide a systematic
analysis of the reciprocal interactions between COX enzyme induc-
tion and inﬂammatory responses to a range of bacterial- and viral-
like stimuli. The ability of Cox2 deletion to suppress physical and
cytokine responses to LPS has been previously reported, and
contrasts strongly with our new data showing that Cox2 deletionenhances IFN responses to viral PAMPs, particularly poly(I:C).
These data suggest a role for COX-2 in limiting the anti-viral cyto-
kine/interferon response to infection, and may provide a plausible
explanation for the previously published data showing that Cox2
deletion/COX-2 inhibition is beneﬁcial in animal models of viral
infection. If a similar mechanism is present in man, COX-2 inhibi-
tors might be a potential anti-viral therapy, able to boost the
endogenous anti-viral response when given soon after infection.
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